Vertex Pulmonary Embolectomy System
Acute Pulmonary Embolism
Pivotal TrialActive
Key Facts
About Jupiter Endovascular
Jupiter Endovascular is a private, clinical-stage medical device company pioneering a proprietary catheter stabilization technology called Transforming Fixation (TFX). Its lead program, the Vertex Pulmonary Embolectomy System, is currently in a pivotal trial (SPIRARE II) for treating pulmonary embolism, with promising early clinical data. The company is well-capitalized, having raised over $40 million in a Series B round led by Sonder Capital, and is led by a seasoned team of medtech executives with extensive experience in bringing cardiovascular devices to market.
View full company profileTherapeutic Areas
Other Acute Pulmonary Embolism Drugs
| Drug | Company | Phase |
|---|---|---|
| APEX-Return Study | AngioDynamics | Safety & Effectiveness Study |
| eTrieve™ PE Kit | Magneto Thrombectomy Solutions | Phase 1 |